Cinven Limited completed the acquisition of unknown majority stake in BioAgilytix Labs, LLC from Caledonia Investments plc, GHO Capital Partners LLP, Cobepa S.A., ASP Capital and others.
December 21, 2021
Share
Cinven Limited agreed to acquire unknown majority stake in BioAgilytix Labs, LLC from Caledonia Investments plc (LSE:CLDN), GHO Capital Partners LLP, Cobepa S.A., ASP Capital and others on November 17, 2021. Upon completion Cobepa, S.A.will remain a significant minority investor in the Company. Jim Datin, will continue in role under the new ownership. Caledonia's gross proceeds are expected to be $183m. The deal is subject to regulatory approval and US anti-trust approvals. Expected to complete in December 2021. BofA Securities, Inc. acted as financial advisor to BioAgilytix Labs, LLC. William Blair & Company, L.L.C. acted as financial advisor to BioAgilytix Labs, LLC. Lazard Ltd (NYSE:LAZ) acted as financial advisor to BioAgilytix Labs, LLC. White & Case LLP acted as legal advisor to BioAgilytix Labs, LLC. Deloitte LLP acted as accountant to BioAgilytix Labs, LLC. Deloitte LLP acted as accountant to GHO Capital Partners LLP. Neill Jakobe, Tim Castelli and Elaine B. Murphy of Ropes & Gray LLP acted as legal advisor to GHO Capital Partners LLP. Michael Chernick from Shearman & Sterling LLP acted as legal advisor for lender Blackstone Alternative Credit Advisors LP.
Cinven Limited completed the acquisition of unknown majority stake in BioAgilytix Labs, LLC from Caledonia Investments plc (LSE:CLDN), GHO Capital Partners LLP, Cobepa S.A., ASP Capital and others on December 21, 2021. As of December 21, 2021 US anti-trust body approved the deal.
Caledonia Investments plc is a United Kingdom-based self-managed investment trust company. The Company holds investments in both listed and private markets, covering a range of sectors and particularly through its fund investments. It invests in managed businesses that combine long-term growth characteristics with, in many cases, an ability to deliver increasing levels of income. It manages assets of circa £2.9 billion across an international, multi-asset portfolio, with a focus on companies that have the potential to generate long-term shareholder value. The Companyâs fund types include private equity funds, funds of private equity (PE) funds, and quoted market funds. It invests in a range of sectors, such as information technology, industrials, consumer staples, materials, healthcare, financials, communication services, utilities, real estate and consumer discretionary. It invests in various regions, such as the United Kingdom, Asia, Europe, and North America.
Cinven Limited completed the acquisition of unknown majority stake in BioAgilytix Labs, LLC from Caledonia Investments plc, GHO Capital Partners LLP, Cobepa S.A., ASP Capital and others.